CORDIS
EU research results

CORDIS

English EN

Evaluation of the prevalence of the coeliac disease and its genetic components in the european population

Project information

Grant agreement ID: QLK1-CT-1999-00037

  • Start date

    1 January 2000

  • End date

    31 March 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 4 936 065

  • EU contribution

    € 3 958 791

Coordinated by:

AMYLUM-BELGIUM NV

Belgium

Objective

TECHNOLOGICAL PROBLEM

Coeliac disease is an autoimmune type disease characterised by intolerance to gluten (gluten is a major food ingredient extracted from cereals like wheat, rye and barley). In genetically susceptible individuals, gluten ingestion results in intestinal mucosa damage and malabsorption of essential nutrients.
The coeliac-EU cluster groups together three research programmes with complementary scientific objectives:
To establish the prevalence of oeliac disease in a large European population.
To characterise the genetic basis of this common food intolerance.
To identify factors involved in the gluten-triggered pathogenesis of mucosal damage.


EXPECTED RESULTS

The epidemiology study will :
Provide an estimate of the prevalence of oeliac disease in Europe.
Allow identification and early treatment of 'silent' oeliac people who are so far not detected.

The genetic study will :
Identify association(s) between gene(s) and the oeliac disease.
Clarify the contribution of the HLA genetic components and their association with other (non-HLA) genetic markers.

The pathogenesis study will :
Characterise features of damage in the oeliac mucosa.
Provide information on factors involved in the pathogenesis of mucosal damage, in particular on T cells involvement.


APPLICATIONS

A new simple serological diagnostic test, suitable for large population screening and allowing an easier and earlier detection of the disease, will be validated.
A non-invasive genetic test based on DNA analysis may potentially be developed in the future.
New therapeutic strategies, for instance based on immuno-modulation, may potentially be developed in the future.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

AMYLUM-BELGIUM NV

Address

10,Burchstraat 10
9300 Aalst

Belgium

Participants (14)

EUROSPITAL S.P.A.

Italy

FINNISH RED CROSS BLOOD TRANSFUSION SERVICE

Finland

GOETEBORG UNIVERSITY

Sweden

GSF-RESEARCH CENTER FOR ENVIRONMENT AND HEALTH

Germany

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

KING'S COLLEGE LONDON

United Kingdom

QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

THE MATHILDA AND TERENCE KENNEDY INSTITUTE OF RHEUMATOLOGY

United Kingdom

UNIVERSITA POLITECNICA DELLE MARCHE

Italy

UNIVERSITY OF ERLANGEN-NUREMBERG

Germany

UNIVERSITY OF OSLO

Norway

UNIVERSITY OF SOUTHAMPTON

United Kingdom

UNIVERSITY OF TAMPERE

Finland

Università degli Studi di Napoli 'Federico II'

Italy

Project information

Grant agreement ID: QLK1-CT-1999-00037

  • Start date

    1 January 2000

  • End date

    31 March 2003

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 4 936 065

  • EU contribution

    € 3 958 791

Coordinated by:

AMYLUM-BELGIUM NV

Belgium